Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Novartis
Chinese Patent Office
Mallinckrodt
Fish and Richardson
Cantor Fitzgerald
Daiichi Sankyo
US Army
Boehringer Ingelheim
Dow
Moodys

Generated: January 19, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 205429

« Back to Dashboard

NDA 205429 describes DAPSONE, which is a drug marketed by Taro, Actavis Llc, Alvogen, Jacobus, Nostrum Labs Inc, Novitium Pharma, and Virtus Pharms, and is included in eight NDAs. It is available from twelve suppliers. Additional details are available on the DAPSONE profile page.

The generic ingredient in DAPSONE is dapsone. There are eight drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the dapsone profile page.
Summary for 205429
Tradename:DAPSONE
Applicant:Alvogen
Ingredient:dapsone
Patents:0
Therapeutic Class:Antimycobacterials
Formulation / Manufacturing:see details
Pharmacology for NDA: 205429
Ingredient-typeSulfones
Medical Subject Heading (MeSH) Categories for 205429
Suppliers and Packaging for NDA: 205429
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
DAPSONE dapsone TABLET;ORAL 205429 ANDA Alvogen Inc. 47781-333 47781-333-31 2 BLISTER PACK in 1 CARTON (47781-333-31) > 15 TABLET in 1 BLISTER PACK
DAPSONE dapsone TABLET;ORAL 205429 ANDA Alvogen Inc. 47781-334 47781-334-31 2 BLISTER PACK in 1 CARTON (47781-334-31) > 15 TABLET in 1 BLISTER PACK

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength25MG
Approval Date:Jan 7, 2016TE:ABRLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength100MG
Approval Date:Jan 7, 2016TE:ABRLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Merck
Fuji
McKesson
Johnson and Johnson
UBS
Cantor Fitzgerald
Cipla
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot